Lexaria Bioscience Corp Stock Research

Market Summary

USD2.86-0.01

Delayedas of 25 Jan 2023, 03:52 pm

-0.35%

LEXX Stock Price

LEXX RSI Chart

LEXX Valuation

Market Cap

16.4M

Price/Earnings (Trailing)

-2.25

Price/Sales (Trailing)

64.08

EV/EBITDA

-2.64

Price/Free Cashflow

-3.35

LEXX Price/Sales (Trailing)

LEXX Profitability

Return on Equity

-91.45%

Return on Assets

-92.79%

Free Cashflow Yield

-29.82%

LEXX Fundamentals

LEXX Revenue

Revenue (TTM)

255.4K

Revenue Y/Y

258.31%

Revenue Q/Q

11.47%

LEXX Earnings

Earnings (TTM)

-7.3M

Earnings Y/Y

-18.74%

Earnings Q/Q

42.16%

Price Action

52 Week Range

1.804.83

(Low)(High)

Last 7 days

3.2%

Last 30 days

17.1%

Last 90 days

38.7%

Trailing 12 Months

-33.3%

LEXX Financial Health

Current Ratio

35.96

LEXX Investor Care

Shares Dilution (1Y)

3.92%

Financials for Lexaria Bioscience

Income Statement (Last 12 Months)					(In Thousands)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Revenue	-31.4%	255	372	489	606	723
Gross Profit	47.6%	184	124	187	325	547
Operating Expenses	7.4%	7,567	7,048	7,329	6,234	-
S&GA Expenses	6.6%	5,725	5,371	5,880	5,772	4,971
R&D Expenses	-4.3%	1,843	1,926	1,629	1,529	1,263
EBITDA	0%	-1,711.87	-1,711.87	-	-	-
EBITDA Margin	0%	-2.37*	-2.37*	-	-	-
EBT Margin	0%	-2.52*	-2.52*	-	-	-
Net Income	-3.6%	-7,269.32	-7,015.36	-7,163.58	-5,333.69	-4,036.56
Net Income Margin	-191.8%	-28.46*	-9.75*	-9.94*	-	-
Free Cahsflow	-2.0%	-4,879.34	-4,781.95	-4,690.51	-	-

* denotes actual numbers (not divided by Thousands)

Balance Sheet					(In Thousands)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Assets	-14.3%	7,834	9,138	11,415	11,746	13,267
Current Assets	-15.8%	6,978	8,291	10,572	10,901	12,443
Cash Equivalents	-17.6%	5,813	7,051	8,359	9,682	10,918
Inventory	-4.4%	38	40	32	27	30
Net PPE	-8.1%	316	343	368	-	-
Liabilities	-10.5%	201	225	195	277	203
Current Liabilities	-6.2%	194	207	166	238	153
Shareholder's Equity	-13.4%	7,949	9,183	11,220	11,469	13,266
Retained Earnings	-3.9%	-39,098.53	-37,631.06	-35,248.14	-33,822.36	-31,829.20
Additional Paid-In Capital	0.5%	47,041	46,809	46,697	45,498	45,089
Accumulated Depreciation	7.9%	380	352	278	-	-
Shares Outstanding	0%	5,951	5,951	5,951	5,727	5,727
Minority Interest	-16.9%	-316.41	-270.72	-235.31	-212.41	-202.08

Cashflow (Last 12 Months)					(In Thousands)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Cashflow From Operations	-1.3%	-4,879.34	-4,814.91	-4,712.49	-4,346.47	-3,989.68
Share Based Compensation	44.8%	753	520	753	770	410
Cashflow From Investing	-38.3%	-180.64	-130.60	-163.37	141	194
Cashflow From Financing	-101.1%	-44.60	3,971	4,016	13,418	13,420

Risks for LEXX

What is the probability of a big loss on LEXX?

100%

Probability that Lexaria Bioscience stock will be more than 20% underwater in next one year

100%

Probability that Lexaria Bioscience stock will be more than 30% underwater in next one year.

100%

Probability that Lexaria Bioscience stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does LEXX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Lexaria Bioscience was unfortunately bought at previous high price.

Drawdowns

Returns for LEXX

Cumulative Returns on LEXX

0.6%

10-Year Cumulative Returns

-42.4%

3-Year Cumulative Returns

What are the long-term rolling returns for LEXX?

FIve years rolling returns for Lexaria Bioscience.

Annualized Returns

Which funds bought or sold LEXX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2022-11-15	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
2022-11-15	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
2022-11-14	BOOTHBAY FUND MANAGEMENT, LLC	unchanged	-	-42,000	193,000	-%
2022-11-14	Centiva Capital, LP	reduced	-6.36	-10,000	32,000	-%
2022-11-14	ADVISOR GROUP HOLDINGS, INC.	unchanged	-	-2,000	5,000	-%
2022-11-14	Invenomic Capital Management LP	added	29.54	71,000	1,159,000	0.10%
2022-11-14	WELLS FARGO & COMPANY/MN	added	0.19	-1,000	2,000	-%
2022-11-14	SABBY MANAGEMENT, LLC	reduced	-16.93	459,000	699,000	0.88%
2022-11-14	Empery Asset Management, LP	unchanged	-	-14,000	74,000	0.44%
2022-11-14	GEODE CAPITAL MANAGEMENT, LLC	reduced	-1.85	-28,000	120,000	-%

Latest Funds Activity

Are funds buying LEXX calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own LEXX

No. of Funds

Lexaria Bioscience News

Schedule 13G FIlings of Lexaria Bioscience

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2022	invenomic capital management lp	6.03%	359,113	SC 13G
Feb 14, 2022	l1 capital global opportunities master fund, ltd.	2.6%	159,000	SC 13G/A
Feb 24, 2021	bunka christopher	9.5%	489,455	SC 13D/A

LEXX Fair Value

Recent SEC filings of Lexaria Bioscience

View All Filings

Date Filed	Form Type	Document
Jan 23, 2023	8-K	Current Report
Jan 18, 2023	10-Q/A	Quarterly Report
Jan 17, 2023	10-Q	Quarterly Report
Jan 17, 2023	8-K	Current Report
Dec 29, 2022	EFFECT	EFFECT
Dec 28, 2022	POS AM	POS AM
Dec 22, 2022	EFFECT	EFFECT
Dec 21, 2022	POS AM	POS AM
Dec 06, 2022	10-K/A	Annual Report
Nov 30, 2022	8-K	Current Report

Latest Insider Trading transactions for LEXX

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2022-10-14	Downey Gregory	acquired	252.89	2.09	121	chief financial officer
2022-10-14	Downey Gregory	bought	252.89	2.09	121	chief financial officer
2022-10-13	BUNKA CHRISTOPHER	acquired	34,860	2.1	16,600	ceo
2022-10-13	BUNKA CHRISTOPHER	bought	34,860	2.1	16,600	chief executive officer
2022-10-12	BUNKA CHRISTOPHER	acquired	43,537.2	1.988	21,900	ceo
2022-10-12	BUNKA CHRISTOPHER	bought	43,537.2	1.988	21,900	chief executive officer
2022-05-24	REESE ALBERT L JR	acquired	9,790	1.958	5,000	-
2022-05-20	REESE ALBERT L JR	acquired	3,610.59	2.007	1,799	-
2022-05-19	REESE ALBERT L JR	acquired	3,017.01	2.01	1,501	-
2022-05-18	REESE ALBERT L JR	acquired	3,413.6	2.008	1,700	-

About Lexaria Bioscience

Christopher A. Bunka

Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

LEXX Income Statement

2022-11-30

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended
	Nov. 30, 2022	Nov. 30, 2021
CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)
Revenue	$ 101,476	$ 13,880
Cost of Goods Sold	15,795	5,570
Gross profit	85,681	8,310
Expenses
Research and development	829,489	458,709
Office and administration	1,025,498	1,553,083
Total operating expenses	1,854,987	2,011,792
Net loss	(1,769,306)	(2,003,482)
Net loss for the period	(1,769,306)	(2,003,482)
Net loss and comprehensive loss attributable to:
Common shareholders	(1,755,944)	(1,993,157)
Non-controlling interest	$ (13,362)	$ (10,325)
Basic and diluted income (loss) per share	$ (0.30)	$ (0.35)
Weighted average number of common shares outstanding
Basic and diluted	$ 5,950,998	$ 5,726,699

LEXX Balance Sheet

2022-11-30

CONSOLIDATED BALANCE SHEET - USD ($)	Nov. 30, 2022	Aug. 31, 2022
Current
Cash	$ 4,533,063	$ 5,813,218
Marketable securities	269,707	347,335
Accounts receivable	286,322	201,784
Inventory	9,936	38,418
Prepaid expenses and deposit	260,342	576,761
Total Current Assets	5,359,370	6,977,516
Non-current assets, net
Right of use assets	42,340	52,444
Intellectual property	500,549	488,462
Property & equipment	311,221	315,505
Total Non-current Assets	854,110	856,411
TOTAL ASSETS	6,213,480	7,833,927
Current
Accounts payable and accrued liabilities	241,891	151,449
Lease payable	39,629	42,587
Total Current Liabilities	281,520	194,036
Long Term
Lease payable	0	7,401
Total Long Term Liabilities	0	7,401
TOTAL LIABILITIES	281,520	201,437
STOCKHOLDERS' EQUITY
Authorized 220,000,000 common voting shares with a par value of $0.001 per share Issued and outstanding: 5,950,998 common shares at November 30, 2022 and at August 31, 2022	5,951	5,951
Additional paid-in capital	47,110,257	47,041,481
Deficit	(40,854,472)	(39,098,528)
Equity attributable to shareholders of the Company	6,261,736	7,948,904
Non-controlling Interest	(329,776)	(316,414)
Total Stockholders' Equity	5,931,960	7,632,490
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 6,213,480	$ 7,833,927